Raymond James & Associates Zai Lab LTD Transaction History

Raymond James & Associates

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 16, 2024	SELL	$22.97 - $30.58 $119,444 - $159,016	-5,200 Reduced 27.55%	13,674 $373,000
Q3 2023 Oct 24, 2023	SELL	$22.72 - $31.49 $11,360 - $15,745	-500 Reduced 2.58%	18,874 $458,000
Q2 2023 Jul 25, 2023	BUY	$25.3 - $39.67 $490,162 - $768,566	19,374 New	19,374 $537,000
Q4 2021 Feb 08, 2022	SELL	$54.9 - $105.21 $128,795 - $246,822	-2,346 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$105.0 - $178.37 $70,770 - $120,221	-674 Reduced 22.32%	2,346 $247,000
Q2 2021 Aug 11, 2021	BUY	$125.11 - $180.0 $129,864 - $186,840	1,038 Added 52.37%	3,020 $535,000
Q1 2021 May 14, 2021	BUY	$126.27 - $191.71 $250,267 - $379,969	1,982 New	1,982 $264,000

146

53M

103K

439K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $3.57B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.